Kinara

1 week ago | kinara.co | Larry Dobrow

Unbranded educational initiatives are essential tools for life sciences companies, but their success can depend heavily on effective collaboration between medical and commercial teams. These campaigns must navigate regulatory constraints while still delivering specific, meaningful content to healthcare professionals. Too often, siloed efforts lead to duplicated work and inconsistent messaging.

2 weeks ago | kinara.co | Larry Dobrow

One-time gene and cell therapies for rare diseases often come with million-dollar price tags, but they also offer the possibility of lifelong cures that replace decades of chronic care. While these therapies are economically rational in the long run, their high upfront costs collide with the short-term incentives and annual budget constraints of payers.

3 weeks ago | kinara.co | Larry Dobrow

Nivi Mogali’s personal losses—her grandmother’s preventable death and the Covid-related deaths of her grandfather and father-in-law—shaped her career in healthcare analytics. Now a senior leader at GSK, she’s known for her ability to translate complex data into actionable insights and for pushing pharma toward faster, more effective analytics frameworks. Her work during the pandemic highlighted her commitment to innovation under pressure.

1 month ago | kinara.co | Larry Dobrow

Once skeptical, the life sciences industry has gradually embraced influencer marketing, recognizing the power of authentic patient and physician voices to drive trust and engagement. Despite early missteps – like the FDA’s rebuke of a Kim Kardashian post – companies have learned to navigate regulatory challenges and now focus on authenticity, compliance and strategic alignment. Influencers are seen as credible conduits for health information, often more impactful than traditional advertising.

1 month ago | kinara.co | Larry Dobrow

Postpartum depression, though referenced as far back as ancient Greece, wasn’t formally recognized in U.S. medicine until 1994 – a delay that underscores how slowly awareness has evolved. Sage Therapeutics CEO Barry Greene discusses how the company’s PPD treatment Zurzuvae marks a paradigm shift by enabling OB/GYNs to screen, diagnose and treat PPD directly, bringing mental health care to the frontlines of maternal care.